Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.106 EUR
−3.52 M EUR
4.64 M EUR
33.04 M
About ABIONYX PHARMA
Sector
CEO
Cyrille Tupin
Headquarters
Balma
Website
Founded
2005
ISIN
FR0012616852
FIGI
BBG00896C9L3
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. It specializes in the development of treatment for cardiovascular and metabolic disorders. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ABNX is 1.348 EUR — it has decreased by −2.32% in the past 24 hours. Watch ABIONYX PHARMA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange ABIONYX PHARMA stocks are traded under the ticker ABNX.
ABNX stock has risen by 7.15% compared to the previous week, the month change is a 10.13% rise, over the last year ABIONYX PHARMA has showed a 11.04% increase.
We've gathered analysts' opinions on ABIONYX PHARMA future price: according to them, ABNX price has a max estimate of 11.50 EUR and a min estimate of 11.50 EUR. Watch ABNX chart and read a more detailed ABIONYX PHARMA stock forecast: see what analysts think of ABIONYX PHARMA and suggest that you do with its stocks.
ABNX reached its all-time high on Jun 1, 2015 with the price of 14.440 EUR, and its all-time low was 0.200 EUR and was reached on Oct 25, 2019. View more price dynamics on ABNX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ABNX stock is 6.15% volatile and has beta coefficient of −0.79. Track ABIONYX PHARMA stock price on the chart and check out the list of the most volatile stocks — is ABIONYX PHARMA there?
Today ABIONYX PHARMA has the market capitalization of 47.85 M, it has increased by 0.33% over the last week.
Yes, you can track ABIONYX PHARMA financials in yearly and quarterly reports right on TradingView.
ABIONYX PHARMA is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
ABNX net income for the last half-year is −2.09 M EUR, while the previous report showed −1.27 M EUR of net income which accounts for −64.41% change. Track more ABIONYX PHARMA financial stats to get the full picture.
No, ABNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIONYX PHARMA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABIONYX PHARMA EBITDA is −4.77 M EUR, and current EBITDA margin is −108.90%. See more stats in ABIONYX PHARMA financial statements.
Like other stocks, ABNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIONYX PHARMA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIONYX PHARMA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIONYX PHARMA stock shows the neutral signal. See more of ABIONYX PHARMA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.